Dergiler / Üroonkoloji Bülteni / 2021 / Cilt: 20 - Sayı: 4

Radical Prostatectomy Outcomes in Patients with Clinical Lymph Node Involvement from The Turkish Urooncology Database

Sayfa
231–235
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Therefore, RP stands as an effective treatment option in selected patients with PCa having clinical lymph node involvement.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aimed to investigate pathological lymph node involvement in selected patients and the relationship of prostate-specific antigen (PSA) progression-free survival rates between patients with and without lymph node involvement on preoperative conventional radiologic imaging.
📊
Temel Bulgular & Veri:Materials and Methods: Using the national PCa database, patients who underwent radical prostatectomy (RP) and pelvic lymph node dissection between 2001 and 2019, with pathologic lymph node involvement, were included in the study.
💡
Sonuç & Katkı:Therefore, RP stands as an effective treatment option in selected patients with PCa having clinical lymph node involvement.
🔬Tür:Araştırma Makalesi
📍Kapsam:2001 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: This study aimed to investigate pathological lymph node involvement in selected patients and the relationship of prostate-specific antigen (PSA) progression-free survival rates between patients with and without lymph node involvement on preoperative conventional radiologic imaging. Limited data is available about local treatment outcomes in patients with prostate cancer (PCa) having clinical lymph node involvement. Materials and Methods: Using the national PCa database, patients who underwent radical prostatectomy (RP) and pelvic lymph node dissection between 2001 and 2019, with pathologic lymph node involvement, were included in the study. Patients were divided into two groups as those with and without clinical lymph node involvement by preoperative imaging. Results: A total of 213 patients were included in the final analysis, wherein 164 are with and 49 are without lymph node involvement. After the mean follow-up periods of 33.9 months, a significant difference was not found between the two groups in terms of recurrence, adjuvant treatment necessity, and final status. The multivariate analysis for 5-year PSA recurrence-free survival revealed that surgical margin positivity was the only significant factor (p=0.016, hazard ratio: 2.67, confidence interval: 1.19-5.98). Conclusion: Our results revealed that preoperative clinical lymph node status did not affect the 5-year PSA recurrence-free survival in pathologic lymph node involvement of patients treated with RP and pelvic lymph node dissection. Therefore, RP stands as an effective treatment option in selected patients with PCa having clinical lymph node involvement.

🔖

Bu Makaleye Atıf Yap

Müezzinoğlu, T., Şahin, B., Baltacı, S., Akdoğan, B., İzol, V., Tinay, İ., Tavukçu, H. H., Yücetaş, U., Erbatu, O., Aslan, G. (2022). Radical Prostatectomy Outcomes in Patients with Clinical Lymph Node Involvement from The Turkish Urooncology Database. Üroonkoloji Bülteni, Cilt: 20 - Sayı: 4, 231–235. https://ajindex.com/articles/645720

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Mottet N, van den Bergh RCN, Briers E, et al, eds. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020., Arnhem: EAU Guidelines Office; 2020
  2. Moschini M, Briganti A, Murphy CR, et al. Eur Urol 2016;69:193-196
  3. Boorjian SA, Thompson RH, Siddiqui S, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007;178:864-870; discussion 70-1
  4. Touijer KA, Mazzola CR, Sjoberg DD, et al. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 2014;65:20-25
  5. Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754-761
  6. Abdollah F, Gandaglia G, Suardi N, et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 2015;67:212-219
  7. Seisen T, Vetterlein MW, Karabon P, et al. Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at ınitial diagnosis. Eur Urol 2018;73:452-461
  8. Gandaglia G, Soligo M, Battaglia A, et al. Which patients with clinically node-positive prostate cancer should be considered for radical prostatectomy as part of multimodal treatment? The impact of nodal burden on long-term outcomes. Eur Urol 2019;75:817-825
  9. Ventimiglia E, Seisen T, Abdollah F, et al. A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur Urol Oncol 2019;2:294-301
  10. Stattin P, Sandin F, Thomsen FB, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol 2017;72:125-134
  11. Denlinger CS, Sanft T, Moslehi JJ, et al. NCCN Guidelines Insights: Survivorship, Version 2.2020: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2020;18:1016-1023.